{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:12:54Z","timestamp":1788484374710,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":227,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bile acid diarrhoea (BAD) is an increasingly recognized cause of chronic diarrhoea. The 75-selenium homocholic acid taurine (SeHCAT) test remains the gold standard for diagnosis. The primary pharmacological treatment involves bile acid\u2013binding agents, most commonly colestyramine. This study aimed to review the management of BAD at our centre and to identify factors associated with response to colestyramine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This single-centre retrospective study included all patients with an abnormal SeHCAT test (retention &amp;lt;15%) from 1 January 2020 to 31 December 2023 associated with chronic diarrhoea. Patients receiving empiric bile acid chelators without prior SeHCAT testing and those under 18\u2009years of age were excluded. The primary endpoint was treatment success with colestyramine, defined as complete or partial clinical response without treatment discontinuation due to intolerance. Univariable comparisons and multivariable logistic regression were performed to identify factors independently associated with treatment success.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ninety-seven patients were included; 72.2% were women, with a mean age of 54.4\u2009\u00b1\u200915.1\u2009years. Severe BAD was observed in 60.8% of cases. Overall, 77.3% of patients responded to colestyramine (43.2% complete, 34.0% partial). In multivariable analysis, baseline higher number of bowel movements per day was independently associated with a lower probability of treatment success (odds ratio 0.79, 95% confidence interval 0.68\u20130.92; P\u2009=\u20090.003). Colestyramine failure was generally due to intolerance-related discontinuation (17.5% of the cohort) followed by lack of efficacy (5.1%). No severe adverse events were documented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Colestyramine appears to be an effective first-line therapy for BAD in routine clinical practice. However, treatment success in this study reflects both clinical response and tolerability, as treatment failure was more frequently related to intolerance than lack of efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/gastro\/goag090","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:41:58Z","timestamp":1786448518000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-world management of SeHCAT-confirmed bile acid diarrhoea: response to colestyramine and predictors of treatment success"],"prefix":"10.1093","volume":"14","author":[{"given":"Eduard","family":"Brunet-Mas","sequence":"first","affiliation":[{"name":"Servei d\u2019Aparell Digestiu, Parc Taul\u00ed Hospital Universitari, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Sabadell, Catalunya, Departament de Medicina, Universitat Aut\u00f2noma de Barcelona , Sabadell 08208,","place":["Spain"]},{"name":"CIBEREHD, Instituto de Salud Carlos III , Madrid 28029,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pe\u00f1a-Rosado","sequence":"additional","affiliation":[{"name":"Servei d\u2019Aparell Digestiu, Parc Taul\u00ed Hospital Universitari, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Sabadell, Catalunya, Departament de Medicina, Universitat Aut\u00f2noma de Barcelona , Sabadell 08208,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belen","family":"Garcia-Sagu\u00e9","sequence":"additional","affiliation":[{"name":"Servei d\u2019Aparell Digestiu, Parc Taul\u00ed Hospital Universitari, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Sabadell, Catalunya, Departament de Medicina, Universitat Aut\u00f2noma de Barcelona , Sabadell 08208,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Enrique","family":"Frisancho","sequence":"additional","affiliation":[{"name":"Servei d\u2019Aparell Digestiu, Parc Taul\u00ed Hospital Universitari, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Sabadell, Catalunya, Departament de Medicina, Universitat Aut\u00f2noma de Barcelona , Sabadell 08208,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Melcarne","sequence":"additional","affiliation":[{"name":"Servei d\u2019Aparell Digestiu, Parc Taul\u00ed Hospital Universitari, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Sabadell, Catalunya, Departament de Medicina, Universitat Aut\u00f2noma de Barcelona , Sabadell 08208,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Patricia","family":"Llovet","sequence":"additional","affiliation":[{"name":"Servei d\u2019Aparell Digestiu, Parc Taul\u00ed Hospital Universitari, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Sabadell, Catalunya, Departament de Medicina, Universitat Aut\u00f2noma de Barcelona , Sabadell 08208,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Puy","sequence":"additional","affiliation":[{"name":"Servei d\u2019Aparell Digestiu, Parc Taul\u00ed Hospital Universitari, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Sabadell, Catalunya, Departament de Medicina, Universitat Aut\u00f2noma de Barcelona , Sabadell 08208,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Ram\u00edrez-L\u00e1zaro","sequence":"additional","affiliation":[{"name":"Servei d\u2019Aparell Digestiu, Parc Taul\u00ed Hospital Universitari, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Sabadell, Catalunya, Departament de Medicina, Universitat Aut\u00f2noma de Barcelona , Sabadell 08208,","place":["Spain"]},{"name":"CIBEREHD, Instituto de Salud Carlos III , Madrid 28029,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rodriguez Revuelto","sequence":"additional","affiliation":[{"name":"Servei de Medicina Nuclear, Parc Taul\u00ed Hospital Universitari, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Sabadell, Catalunya, Departament de Medicina, Universitat Aut\u00f2noma de Barcelona , Sabadell 08208,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Villoria","sequence":"additional","affiliation":[{"name":"Servei d\u2019Aparell Digestiu, Parc Taul\u00ed Hospital Universitari, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Sabadell, Catalunya, Departament de Medicina, Universitat Aut\u00f2noma de Barcelona , Sabadell 08208,","place":["Spain"]},{"name":"CIBEREHD, Instituto de Salud Carlos III , Madrid 28029,","place":["Spain"]},{"name":"Departament de Medicina, Universitat Aut\u00f2noma de Barcelona , Bellaterra 08193,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Calvet","sequence":"additional","affiliation":[{"name":"Servei d\u2019Aparell Digestiu, Parc Taul\u00ed Hospital Universitari, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Sabadell, Catalunya, Departament de Medicina, Universitat Aut\u00f2noma de Barcelona , Sabadell 08208,","place":["Spain"]},{"name":"CIBEREHD, Instituto de Salud Carlos III , Madrid 28029,","place":["Spain"]},{"name":"Departament de Medicina, Universitat Aut\u00f2noma de Barcelona , Bellaterra 08193,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Lario","sequence":"additional","affiliation":[{"name":"Servei d\u2019Aparell Digestiu, Parc Taul\u00ed Hospital Universitari, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Sabadell, Catalunya, Departament de Medicina, Universitat Aut\u00f2noma de Barcelona , Sabadell 08208,","place":["Spain"]},{"name":"CIBEREHD, Instituto de Salud Carlos III , Madrid 28029,","place":["Spain"]},{"name":"Departament de Gen\u00e8tica i Microbiologia, Universitat Aut\u00f2noma de Barcelona , Bellaterra 08193,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"2026090320280740300_goag090-B1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev.me.18.020167.002001","article-title":"Detergent properties of bile salts: correlation with physiological function","volume":"18","author":"Hofmann","year":"1967","journal-title":"Annu Rev Med"},{"key":"2026090320280740300_goag090-B2","doi-asserted-by":"publisher","author":"Maqsood","DOI":"10.7759\/cureus.108847"},{"key":"2026090320280740300_goag090-B3","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0016-5085(67)80140-9","article-title":"The syndrome of ileal disease and the broken enterohepatic circulation: cholerheic enteropathy","volume":"52","author":"Hofmann","year":"1967","journal-title":"Gastroenterology"},{"key":"2026090320280740300_goag090-B4","author":"Wortmann"},{"key":"2026090320280740300_goag090-B5","doi-asserted-by":"crossref","first-page":"332","DOI":"10.5009\/gnl14397","article-title":"Bile acid diarrhea: prevalence, pathogenesis, and therapy","volume":"9","author":"Camilleri","year":"2015","journal-title":"Gut Liver"},{"key":"2026090320280740300_goag090-B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cgh.2009.10.020","article-title":"Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function","volume":"8","author":"Odunsi-Shiyanbade","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026090320280740300_goag090-B7","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s10620-006-9090-8","article-title":"Taurodeoxycholate modulates apical Cl-\/OH- exchange activity in Caco2 cells","volume":"52","author":"Alrefai","year":"2007","journal-title":"Dig Dis Sci"},{"key":"2026090320280740300_goag090-B8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.gastro.2012.09.055","article-title":"The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice","volume":"144","author":"Alemi","year":"2013","journal-title":"Gastroenterology"},{"key":"2026090320280740300_goag090-B9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/1756283X10377126","article-title":"Managing bile acid diarrhoea","volume":"3","author":"Walters","year":"2010","journal-title":"Ther Adv Gastroenterol"},{"key":"2026090320280740300_goag090-B10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2036.2009.04081.x","article-title":"Systematic review: The prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome","volume":"30","author":"Wedlake","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"2026090320280740300_goag090-B11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cgh.2019.08.062","article-title":"Canadian association of gastroenterology clinical practice guideline on the management of bile acid diarrhea","volume":"18","author":"Sadowski","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026090320280740300_goag090-B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4303\/ne\/235657","article-title":"Effect of cholestyramine on gastrointestinal transit in patients with idiopathic bile acid diarrhea: a prospective, open-label study","volume":"2","author":"Stotzer","year":"2013","journal-title":"Neuroenterology"},{"key":"2026090320280740300_goag090-B13","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1155\/2013\/485631","article-title":"Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment","volume":"27","author":"Barkun","year":"2013","journal-title":"Can J Gastroenterol"},{"key":"2026090320280740300_goag090-B14","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.3748\/wjg.v24.i21.2320","article-title":"Obeticholic acid for severe bile acid diarrhea with intestinal failure: a case report and review of the literature","volume":"24","author":"Hvas","year":"2018","journal-title":"World J Gastroenterol"},{"key":"2026090320280740300_goag090-B15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/apt.12999","article-title":"The response of patients with bile acid diarrhoea to the farnesoid x receptor agonist obeticholic acid","volume":"41","author":"Walters","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2026090320280740300_goag090-B16","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/apt.13570","article-title":"Review article: Bile acid diarrhoea\u2014pathogenesis, diagnosis and management","volume":"43","author":"Mottacki","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2026090320280740300_goag090-B17","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1053\/j.gastro.2019.04.002","article-title":"Remission of bile acid malabsorption symptoms following treatment with the glucagon-like peptide 1 receptor agonist liraglutide","volume":"157","author":"K\u00e5rhus","year":"2019","journal-title":"Gastroenterology"},{"key":"2026090320280740300_goag090-B18","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S2468-1253(22)00198-4","article-title":"Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial","volume":"7","author":"K\u00e5rhus","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026090320280740300_goag090-B19","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cgh.2025.03.016","article-title":"Remission of sequestrant-refractory bile acid diarrhea in patients on liraglutide with pragmatic dose escalation: a case series","volume":"24","author":"Borup","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026090320280740300_goag090-B20","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1080\/00365521.2026.2661978","article-title":"Semaglutide for treatment of intractable diarrhea of different etiologies: a case series of 30 patients","volume":"61","author":"Nielsen","year":"2026","journal-title":"Scand J Gastroenterol"},{"key":"2026090320280740300_goag090-B21","first-page":"252","article-title":"Quantifying bile acid malabsorption helps predict response and tailor sequestrant therapy","volume":"15","author":"Orekoya","year":"2015","journal-title":"Clin Med J R Coll Physicians Lond"},{"key":"2026090320280740300_goag090-B22","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"Association","year":"2013","journal-title":"JAMA"},{"key":"2026090320280740300_goag090-B23","doi-asserted-by":"crossref","first-page":"e1001885","DOI":"10.1371\/journal.pmed.1001885","article-title":"The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med"},{"key":"2026090320280740300_goag090-B24","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/apt.12684","article-title":"Systematic review: the management of chronic diarrhoea due to bile acid malabsorption","volume":"39","author":"Wilcox","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"2026090320280740300_goag090-B25","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/apt.15099","article-title":"Systematic review with meta-analysis: the prevalence of bile acid malabsorption and response to colestyramine in patients with chronic watery diarrhoea and previous cholecystectomy","volume":"49","author":"Ruiz-Campos","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2026090320280740300_goag090-B26","doi-asserted-by":"crossref","first-page":"e137\u201340","DOI":"10.1016\/j.ejim.2011.08.013","article-title":"Bile acid malabsorption investigated by selenium-75-homocholic acid taurine (75SeHCAT) scans: causes and treatment responses to cholestyramine in 298 patients with chronic watery diarrhoea","volume":"22","author":"Borghede","year":"2011","journal-title":"Eur J Intern Med"},{"key":"2026090320280740300_goag090-B27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17610","article-title":"SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis","volume":"17","author":"Riemsma","year":"2013","journal-title":"Health Technol Assess"},{"key":"2026090320280740300_goag090-B28","doi-asserted-by":"crossref","first-page":"2097359","DOI":"10.1155\/2018\/2097359","article-title":"Pros and cons of the SeHCAT test in bile acid diarrhea: a more appropriate use of an old nuclear medicine technique","volume":"2018","author":"Fani","year":"2018","journal-title":"Gastroenterol Res Pract"},{"key":"2026090320280740300_goag090-B29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s12876-022-02404-9","article-title":"The impact of treatment with bile acid sequestrants on quality of life in patients with bile acid diarrhoea","volume":"22","author":"Kumar","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"2026090320280740300_goag090-B30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S2468-1253(22)00401-0","article-title":"Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial","volume":"8","author":"Borup","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Gastroenterology Report"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goag090\/70949785\/goag090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goag090\/70949785\/goag090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:28:19Z","timestamp":1788481699000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/gastro\/article\/doi\/10.1093\/gastro\/goag090\/8785266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":30,"URL":"https:\/\/doi.org\/10.1093\/gastro\/goag090","relation":{},"ISSN":["2052-0034"],"issn-type":[{"value":"2052-0034","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,20]]},"article-number":"goag090"}}